Cure8 research brief
An oral IL-23 receptor blocker could offer an alternative to injectable IL-23–targeting therapies for people with moderate-to-severe ulcerative colitis. The phase IIb ANTHEM-UC trial tested icotrokinra’s efficacy and safety and is relevant to patients considering future oral options.
Adults with ulcerative colitis, patients seeking oral therapies, clinicians managing moderate-to-severe UC, and IBD researchers and drug developers.
This Nature Reviews piece previews results from the phase IIb ANTHEM-UC trial (NCT06049017) and cites the primary trial report in NEJM. The trial randomized 252 adults to once-daily oral icotrokinra (100, 200, 400 mg) or placebo with clinical response at week 12 as the primary endpoint.
Secondary endpoints included clinical remission, symptom remission, and endoscopic improvement at week 12. The article is a journal commentary/preview summarizing the trial; it does not provide full patient-level data in the extracted text here.
For details about efficacy, safety, and subgroup findings, consult the NEJM trial report cited in the piece or full-text access to the Nature Reviews article.
The Nature Reviews item is a preview/commentary summarizing a phase II trial; the primary trial report in NEJM should be consulted for full efficacy and safety data. The article text here is an extracted summary, not the complete trial publication.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials...
An oral IL-23 blocker showed benefit in a Phase IIb trial for moderate-to-severe ulcerative colitis, which could add a new pill option for patients—especially those who’ve failed injectable biologics.
If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...
